Ovarian Cancer Clinical Trial
Official title:
A Randomized, Prospective Phase III Comparison of Paclitaxel-Carboplatin Versus Docetaxel-Carboplatin as First Line Chemotherapy in Stage Ic-IV Epithelial Ovarian Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. Combining more than one drug may kill more cancer cells. It is
not yet known which combination chemotherapy regimen is more effective for treating ovarian
epithelial cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of carboplatin plus
paclitaxel with that of carboplatin plus docetaxel in treating patients who have ovarian
epithelial cancer.
OBJECTIVES: I. Compare the progression free survival of chemotherapy naive patients with
stage IC-IV ovarian epithelial cancer following initial surgery treated with paclitaxel and
carboplatin versus docetaxel and carboplatin. II. Compare the toxic effects of these
regimens in these patients. III. Determine the overall survival, overall response rate, and
CA125 response in these patients after these regimens. IV. Determine the quality of life of
these patients on these regimens.
OUTLINE: This is a randomized, multicenter study. Patients are stratified by residual
disease (none or microscopic vs macroscopic no greater than 2 cm vs or macroscopic greater
than 2 cm), study center, FIGO stage (IC-IV), performance status (0 vs 1 vs 2), tumor grade
(well-defined vs moderately defined vs poorly defined/undifferentiated vs unknown), interval
debulking intention (yes vs no vs randomized into OV06 trial), elevated CA125 prior to
treatment (yes vs no), and primary peritoneal cancer (yes vs no). Patients may undergo
interval debulking surgery within 4 weeks of the third course of chemotherapy, or following
6 courses of treatment. Patients undergoing interval debulking after 3 courses should resume
chemotherapy within 3 weeks of surgery. Patients are randomized into one of two treatment
arms. Arm I: Patients receive paclitaxel IV over 3 hours, immediately followed by
carboplatin IV over 1 hour. Arm II: Patients receive docetaxel IV over 1 hour, immediately
followed by carboplatin IV over 1 hour. Courses are repeated every 21 days. Treatment
continues for 6 courses in the absence of disease progression or unacceptable toxicity.
Patients with partial or complete response may receive 3 additional courses of carboplatin
alone thereafter. Quality of life is assessed at baseline, prior to each treatment course,
and then every 4 months for 2 years or until disease progression. Patients are followed
every 2 months for 2 years, every 3 months for 1 year, every 4 months for 1 year, and then
every 6 months thereafter.
PROJECTED ACCRUAL: Approximately 1050 patients will be accrued for this study within 2.25
years.
;
Allocation: Randomized, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
| Withdrawn |
NCT05201001 -
APX005M in Patients With Recurrent Ovarian Cancer
|
Phase 2 | |
| Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
| Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
| Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05156892 -
Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer
|
Phase 1 | |
| Suspended |
NCT02432378 -
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04533763 -
Living WELL: A Web-Based Program for Ovarian Cancer Survivors
|
N/A | |
| Active, not recruiting |
NCT03371693 -
Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer
|
Phase 3 | |
| Withdrawn |
NCT03032614 -
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
|
Phase 2 | |
| Completed |
NCT01936363 -
Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
|
Phase 2 | |
| Completed |
NCT02019524 -
Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients
|
Phase 1 | |
| Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
| Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
| Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
| Terminated |
NCT03146663 -
NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
|
Phase 2 |